HLA-G expression in hematologic malignancies

Expert Review of Hematology

Volumn 3, Issue 1, 2010, Pages 67-80

  Yan, Wei Hua ^a  

^a TAIZHOU HOSPITAL OF ZHEJIANG PROVINCE   (China)

Author keywords

Hematologic malignancies; HLA G; Immune evasion; Prognosis; SHLA G

Indexed keywords

CYTOKINE; HLA G ANTIGEN; HLA G ANTIGEN RECEPTOR; RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; DISEASE ASSOCIATION; DISEASE COURSE; DNA MODIFICATION; EPIGENETICS; GENE; GENE STRUCTURE; HEMATOLOGIC MALIGNANCY; HLA G GENE; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; LYMPHOMA; NEOPLASM; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; RISK FACTOR; SUPPRESSOR CELL;

HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; LEUKEMIA, LYMPHOID; LEUKEMIA, MYELOID; LYMPHOMA;

EID: 77953384545     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.09.72     Document Type: Review

References (110)

1. Dunn GP, Bruce AT, Ikeda H et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3(11), 991-998 (2002).
2. Gomes AQ, Correia DV, Silva-Santos B. Non-classical major histocompatibility complex proteins as determinants of tumour immunosurveillance. EMBO Rep. 8(11), 1024-1030 (2007).
3. Tripathi P, Agrawal S. Non-classical HLA-G antigen and its role in the cancer progression. Cancer Invest. 24(2), 178-186 (2006).
4. Rouas-Freiss N, Moreau P, Ferrone S et al. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res. 65 (22), 10139-10144 (2005).
5. Carosella ED, HoWangYin KY, Favier B et al. HLA-G-dependent suppressor cells: Diverse by nature, function, and significance. Hum. Immunol. 69 (11), 700-707 (2008).
6. Paul P, Rouas-Freiss N, Khalil-Daher I et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc. Natl Acad. Sci. USA 95(8), 4510-4515 (1998).
7. Li BL, Lin A, Zhang XJ et al. Characterization of HLA-G expression in renal cell carcinoma. Tissue Antigens 74(3), 213-221 (2009).
8. Singer G, Rebmann V, Chen YC et al. HLA-G is a potential tumor marker in malignant ascites. Clin. Cancer Res. 9(12), 4460-4464 (2003).
9. Rebmann V, Regel J, Stolke D et al. Secretion of sHLA-G molecules in malignancies. Semin. Cancer Biol. 13(5), 371-377 (2003).
10. Lin A, Zhu CC, Chen HX et al. Clinical relevance and functional implications for human leukocyte antigen-G expression in non-small-cell lung cancer. J. Cell. Mol. Med. DOI: 10.1111/j.1582- 4934.2009.00858.x (2009) (Epub ahead of print).
11. Lin A, Yan WH, Xu HH et al. HLA-G expression in human ovarian carcinoma counteracts NK cell function. Ann. Oncol. 18(11), 1804-1809 (2007).
12. Cai MY, Xu YF, Qiu SJ et al. Human leukocyte antigen-G protein expression is an unfavorable prognostic predictor of hepatocellular carcinoma following curative resection. Clin. Cancer Res. 15(14), 4686-4693 (2009).
13. Urosevic M, Willers J, Mueller B et al. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood 99(2), 609-617 (2002).
14. Rouas-Freiss N, Moreau P, Menier C et al. Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. Semin. Cancer Biol. 17(6), 413-421 (2007).
15. Urosevic M, Dummer R. Human leukocyte antigen-G and cancer immunoediting. Cancer Res. 68(3), 627-630 (2008).
16. Moreau P, Flajollet S, Carosella ED. Nonclassical transcriptional regulation of HLA-G: an update. J. Cell. Mol. Med. DOI: 10.1111/j.1582-4934. 2009.00800.x (2009) (Epub ahead of print).
17. Gobin SJ, van den Elsen PJ. The regulation of HLA class I expression: is HLA-G the odd one out? Semin. Cancer Biol. 9(1), 55-59 (1999).
18. Mizuno S, Emi N, Kasai M et al. Aberrant expression of HLA-G antigen in interferon g-stimulated acute myelogenous leukaemia. Br. J. Haematol. 111(1), 280-282 (2000).
19. Yan WH, Lin A, Chen BG et al. Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia. J. Cell. Mol. Med. 12(3), 889-898 (2008).
20. Gros F, Sebti Y, de Guibert S et al. Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages. Neoplasia 8(3), 223-230 (2006).
21. Nückel H, Rebmann V, Dürig J et al. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 105(4), 1694-1698 (2005).
22. Perez-Chacon G, Rosado S, Rebolleda N et al. Prognostic irrelevance of HLA-G in B-cell chronic lymphocytic leukemia. Int. J. Lab. Hematol. 31(3), 327-337 (2009).
23. Maki G, Hayes GM, Naji A et al. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G. Leukemia 22(5), 998-1006 (2008).
24. Diepstra A, Poppema S, Boot M et al. HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin's lymphoma. Tissue Antigens 71(3), 219-226 (2008).
25. Carosella ED, Favier B, Rouas-Freiss N et al. Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood 111(10), 4862-4870 (2008).
26. Geraghty DE, Koller BH, Orr HT. A human major histocompatibility complex class I gene that encodes a protein with shortened cytoplasmic segment. Proc. Natl Acad. Sci. USA 84(24), 9145-9149 (1987).
27. Carosella ED, Moreau P, Le Maoult J et al. HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv. Immunol. 81, 199-252 (2003).
28. Paul P, Cabestre FA, Ibrahim EC et al. Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells. Hum. Immunol. 61(11), 1138-1149 (2000).
29. Park GM, Lee S, Park B et al. Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis. Biochem. Biophys. Res. Commun. 313(3), 606-611 (2004).
30. Rebmann V, Busemann A, Lindemann M et al. Detection of HLA-G5 secreting cells. Hum. Immunol. 64 (11), 1017-1024 (2003).
31. Ishitani A, Geraghty DE. Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. Proc. Natl Acad. Sci. USA 89(9), 3947-3951 (1992).
32. Colonna M, Navarro F, Bellón T et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J. Exp. Med. 186(11), 1809-1818 (1997).
33. Colonna M, Samaridis J, Cella M et al. Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J. Immunol. 160(7), 3096-3100 (1998).
34. Rajagopalan S, Long EO. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J. Exp. Med. 189(7), 1093-1100 (1999).
35. Goodridge JP, Witt CS, Christiansen FT et al. KIR2DL4 (CD158d) genotype influences expression and function in NK cells. J. Immunol. 171(4), 1768-1774 (2003).
36. Kikuchi-Maki A, Yusa S Catina TL et al. KIR2DL4 is an IL-2-regulated NK cell receptor that exhibits limited expression in humans but triggers strong IFN-g production. J. Immunol. 171(7), 3415-3425 (2003).
37. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 22(11), 633-640 (2001).
38. Shiroishi M, Tsumoto K, Amano K et al. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc. Natl Acad. Sci. USA 100(15), 8856-8861 (2003).
39. Yan WH, Fan LA. Residues Met76 and Gln79 in HLA-G a1 domain involve in KIR2DL4 recognition. Cell Res. 15(3), 176-182 (2005).
40. Pistoia V, Morandi F, Wang X et al. Soluble HLA-G: are they clinically relevant? Semin. Cancer Biol. 17(6), 469-479 (2007).
41. Fons P, Chabot S, Cartwright JE et al. Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. Blood 108 (8), 2608-2615 (2006).
42. Rajagopalan S, Bryceson YT, Kuppusamy SP et al. Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol. 4(1), E9 (2006).
43. Gros F, Cabillic F, Toutirais O et al. Soluble HLA-G molecules impair natural killer/dendritic cell crosstalk via inhibition of dendritic cells. Eur. J. Immunol. 38(3), 742-749 (2008).
44. Riteau B, Rouas-Freiss N, Menier C et al. HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis. J. Immunol. 166(8), 5018-5026 (2001).
45. Hunt JS, Jadhav L, Chu W et al. Soluble HLA-G circulates in maternal blood during pregnancy. Am. J. Obstet. Gynecol. 183(3), 682-688 (2000).
46. Lila N, Amrein C, Guillemain R et al. Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection. Circulation 105 (16), 1949-1954 (2002).
47. Menier C, Rabreau M, Challier JC et al. Erythroblasts secrete the nonclassical HLA-G molecule from primitive to definitive hematopoiesis. Blood 104(10), 3153-3160 (2004).
48. Menier C, Guillard C, Cassinat B et al. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera. Leukemia 22(3), 578-584 (2008).
49. Carosella ED, Moreau P, Lemaoult J et al. HLA-G: from biology to clinical benefits. Trends Immunol. 29(3), 125-132 (2008).
50. Bernstein CN, Blanchard JF, Kliewer E et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91(4), 854-862 (2001).
51. Torres MI, Le Discorde M, Lorite P et al. Expression of HLA-G in inflammatory bowel disease provides a potential way to distinguish between ulcerative colitis and Crohn's disease. Int. Immunol. 16 (4), 579-583 (2004).
52. Leleu X, Le Friec G, Facon T et al. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance. Clin. Cancer Res. 11(20), 7297-7303 (2005).
53. Poláková K, Krcová M, Kuba D et al. Analysis of HLA-G expression in malignant hematopoetic cells from leukemia patients. Leuk. Res. 27(7), 643-648 (2003).
54. Polakova K, Bandzuchova E, Sabty FA et al. Activation of HLA-G expression by 5-aza-2́-deoxycytidine in malignant hematopoetic cells isolated from leukemia patients. Neoplasma 56(6), 514-520 (2009).
55. Amiot L, Onno M, Drénou B et al. HLA-G class I gene expression in normal and malignant hematopoietic cells. Hum. Immunol. 59(8), 524-528 (1998).
56. Amiot L, Le Friec G, Sebti Y et al. HLA-G and lymphoproliferative disorders. Semin. Cancer Biol. 13(5), 379-385 (2003).
57. Erikci AA, Karagoz B, Ozyurt M et al. HLA-G expression in B chronic lymphocytic leukemia: a new prognostic marker? Hematology 14(2), 101-105 (2009).
58. Giannopoulos K, Dmoszynska A, Bojarska- Junak A et al. Expression of HLA-G in patients with B-cell chronic lymphocytic leukemia (B-CLL). Folia. Histochem. Cytobiol. 46(4), 457-460 (2008).
59. Oudejans JJ, Jiwa NM, Kummer JA et al. Analysis of major histocompatibility complex class I expression on Reed- Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and -negative Hodgkin's disease. Blood 87(9), 3844-3851 (1996).
60. Lee SP, Constandinou CM, Thomas WA et al. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: Analysis of the HLA class I processing pathway and the effects of interleukin-10 on epstein-barr virus-specific cytotoxic T-cell recognition. Blood 92(3), 1020-1030 (1998).
61. Murray PG, Constandinou CM, Crocker J et al. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease. Blood 92(7), 2477-2483 (1998).
62. Amiot L, Onno M, Lamy T et al. Loss of HLA molecules in B lymphomas is associated with an aggressive clinical course. Br. J. Haematol. 100(4), 655-663 (1998).
63. Drénou B, Le Friec G, Bernard M et al. Major histocompatibility complex abnormalities in non-Hodgkin lymphomas. Br. J. Haematol. 119(2), 417-424 (2002).
64. Urosevic M, Kamarashev J, Burg G et al. Primary cutaneous CD8+ and CD56+ T-cell lymphomas express HLA-G and killer-cell inhibitory ligand, ILT2. Blood 103(5), 1796-1798 (2004).
65. Moreau P, Rousseau P, Rouas-Freiss N et al. HLA-G protein processing and transport to the cell surface. Cell. Mol. Life Sci. 59(9), 1460-1466 (2002).
66. Mallet V, Pröll J, Solier C et al. The full length HLA-G1 and no other alternative form of HLA-G is expressed at the cell surface of transfected cells. Hum. Immunol. 61(3), 212-224 (2000).
67. Bainbridge DR, Ellis SA, Sargent IL. The short forms of HLA-G are unlikely to play a role in pregnancy because they are not expressed at the cell surface. J. Reprod. Immunol. 47(1), 1-16 (2000).
68. Hviid TV. HLA-G in human reproduction: aspects of genetics, function and pregnancy complications. Hum. Reprod. Update 12(3), 209-232 (2006).
69. Dong Y, Lieskovska J, Kedrin D et al. Soluble nonclassical HLA generated by the metalloproteinase pathway. Hum. Immunol. 64(8), 802-810 (2003).
70. Baricordi OR, Stignani M, Melchiorri L et al. HLA-G and inflammatory diseases. Inflamm. Allergy Drug Targets 7(2), 67-74 (2008).
71. Le Bouteiller P, Tabiasco J, Parinaud J. Soluble HLA-G and embryo implantation: frequently asked questions. Gynecol. Obstet. Invest. 64(3), 134-137 (2007).
72. Solier C, Aguerre-Girr M, Lenfant F et al. Secretion of pro-apoptotic intron 4-retaining soluble HLA-G1 by human villous trophoblast. Eur. J. Immunol. 32(12), 3576-3586 (2002).
73. Rebmann V, Pfeiffer K, Pässler M et al. Detection of soluble HLA-G molecules in plasma and amniotic fluid. Tissue Antigens 53(1), 14-22 (1999).
74. Chen XY, Yan WH, Lin A et al. The 14 bp deletion polymorphisms in HLA-G gene play an important role in the expression of soluble HLA-G in plasma. Tissue Antigens 72(4), 335-341 (2008).
75. Ugurel S, Rebmann V, Ferrone S et al. Soluble human leukocyte antigen - G serum level is elevated in melanoma patients and is further increased by interferon-a immunotherapy. Cancer 92(2), 369-376 (2001).
76. Sebti Y, Le Maux A, Gros F et al. Expression of functional soluble human leucocyte antigen-G molecules in lymphoproliferative disorders. Br. J. Haematol. 138(2), 202-212 (2007).
77. Giannopoulos K, Schmitt M, Kowal M et al. The significance of soluble HLA-G plasma levels as well as messenger HLA-G for B-cell chronic lymphocytic leukemia (B-CLL). Leuk. Res. 32(12), 1815-1819 (2008).
78. Yong P, Kim SJ, Lee SJ et al. Serum level of soluble human leukocyte antigen-G molecules in non-Hodgkin lymphoma: does it have a prognostic value? Leuk. Lymphoma 49(8), 1623-1626 (2008).
79. Chang CC, Ferrone S. HLA-G in melanoma: can the current controversies be solved? Semin. Cancer Biol. 13(5), 361-369 (2003).
80. Gobin SJ, van den Elsen PJ. Transcriptional regulation of the MHC class Ib genes HLA-E, HLA-F, and HLA-G. Hum. Immunol. 61(11), 1102-1107(2000).
81. Gobin SJ, Biesta P, de Steenwinkel JE et al. HLA-G transactivation by cAMP-response element-binding protein (CREB). An alternative transactivation pathway to the conserved major histocompatibility complex (MHC) class I regulatory routes. J. Biol. Chem. 277(42), 39525-39531 (2002).
82. Langat DK, Morales PJ, Omwandho CO et al. Polymorphisms in the Paan-AG promoter influence NF-kB binding and transcriptional activity. Immunogenetics 59(5), 359-366 (2007).
83. Moreau P, Adrian-Cabestre F, Menier C et al. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int. Immunol. 11(5), 803-811 (1999).
84. Urosevic M, Dummer R. HLA-G and IL-10 expression in human cancer - different stories with the same message. Semin. Cancer Biol. 13(5), 337-342 (2003).
85. Sebti Y, Le Friec G, Pangault C et al. Soluble HLA-G molecules are increased in lymphoproliferative disorders. Hum. Immunol. 64(11), 1093-1101(2003).
86. Zhang C, Tian ZG, Wei HM et al. The expression of non-classical class I molecules (HLA-G and HLA-E) in human tumor cell lines and the regulatory effect of IFN-g. Chin. J. Clin. Oncol. (China) 28(4), 247-253 (2001).
87. Lefebvre S, Berrih-Aknin S, Adrian F et al. A specific interferon (IFN)-stimulated response element of the distal HLA-G promoter binds IFN-regulatory factor 1 and mediates enhancement of this nonclassical class I gene by IFN-b. J. Biol. Chem. 276(9), 6133-6139 (2001).
88. Moreau P, Mouillot G, Rousseau P et al. HLA-G gene repression is reversed by demethylation. Proc. Natl Acad. Sci. USA 100(3), 1191-1196 (2003).
89. Sadikovic B, Al-Romaih K, Squire JA et al. Cause and consequences of genetic and epigenetic alterations in human cancer. Curr. Genomics 9(6), 394-408 (2008).
90. Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol. Cancer Ther. 8(6), 1409-1420 (2009).
91. Malmberg KJ, Levitsky V, Norell H et al. IFN-g protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J. Clin. Invest. 110(10), 1515-1523 (2002).
92. Polakova K, Bandzuchova E, Tirpakova J et al. Modulation of HLA-G expression. Neoplasma 54(6), 455-462 (2007).
93. Guillaudeux T, Rodriguez AM, Girr M et al. Methylation status and transcriptional expression of the MHC class I loci in human trophoblast cells from term placenta. J. Immunol. 154(7), 3283-3299 (1995).
94. Onno M, Amiot L, Bertho N et al. CpG methylation patterns in the 5́ part of the nonclassical HLA-G gene in peripheral blood CD34+ cells and CD2+ lymphocytes. Tissue Antigens 49(4), 356-364 (1997).
95. Poláková K, Bandzuchová E, Kuba D et al. Demethylating agent 5-aza-2́- deoxycytidine activates HLA-G expression in human leukemia cell lines. Leuk. Res. 33(4), 518-524 (2009).
96. Yan WH, Lin AF, Chang CC et al. Induction of HLA-G expression in a melanoma cell line OCM-1A following the treatment with 5-aza- 2́-deoxycytidine. Cell Res. 15(7), 523-531 (2005).
97. Piekarz RL, Bates SE. Epigenetic modifiers: basic understanding and clinical development. Clin. Cancer Res. 15(12), 3918-3926 (2009).
98. Fonsatti E, Nicolay HJ, Sigalotti L et al. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2́- deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin. Cancer Res. 13(11), 3333-3338 (2007).
99. Wagner SN, Rebmann V, Willers CP et al. Expression analysis of classic and non-classic HLA molecules before interferon a-2b treatment of melanoma. Lancet 356(9225), 220-221 (2000).
100. Sheshgiri R, Gustafsson F, Sheedy J et al. Everolimus but not mycophenolate mofetil therapy is associated with soluble HLA-G expression in heart transplant patients. J. Heart Lung Transplant. DOI: 10.1016/j. healun.2009 (2009) (Epub ahead of print).
101. Rizzo R, Rubini M, Govoni M et al. HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis. Pharmacogenet. Genomics 16(9), 615-623 (2006).
102. Ciprandi G, Contini P, Pistorio A et al. Sublingual immunotherapy reduces soluble HLA-G and HLA-A, -B, -C serum levels in patients with allergic rhinitis. Int. Immunopharmacol. 9(2), 253-257 (2009).
103. Ciprandi G, Continia P, Fenoglio D et al. Relationship between soluble HLA-G and HLA-A,-B,-C serum levels, and interferon-g production after sublingual immunotherapy in patients with allergic rhinitis. Hum. Immunol. 69(7), 409-413 (2008).
104. Mouillot G, Marcou C, Zidi I et al. Hypoxia modulates HLA-G gene expression in tumor cells. Hum. Immunol. 68(4), 277-285 (2007).
105. Yie SM, Li LH, Li GM et al. Progesterone enhances HLA-G gene expression in JEG-3 choriocarcinoma cells and human cytotrophoblasts in vitro. Hum. Reprod. 21(1), 46-51 (2006).
106. Yie SM, Xiao R, Librach CL. Progesterone regulates HLA-G gene expression through a novel progesterone response element. Hum. Reprod. 21(10), 2538-2544 (2006).
107. Sheshgiri R, Rao V, Tumiati LC et al. Progesterone induces human leukocyte antigen-g expression in vascular endothelial and smooth muscle cells. Circulation 118(14 Suppl.), S58-S64 (2008).
108. Rizzo R, Ferrari D, Melchiorri L et al. Extracellular ATP acting at the P2X7 receptor inhibits secretion of soluble HLA-G from human monocytes. J. Immunol. 183(7), 4302-4311 (2009).
109. Tan Z, Randall G, Fan J et al. Allele-specific targeting of microRNAs to HLA-G and risk of asthma. Am. J. Hum. Genet. 81(4), 829-834 (2007).
110. Veit TD, Chies JA. Tolerance versus immune response-microRNAs as important elements in the regulation of the HLA-G gene expression. Transpl. Immunol. 20(4), 229-231 (2009).